Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Head of Finance

Chief Operating Officer

See Remarks

Chief Financial Officer

Chief Medical Officer

Chief Scientific Officer

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabol...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-02	Premium	sold	Premium	Premium	Premium	Head of Finance
2024-04-02	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-04-03	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-04-03	Premium	sold	Premium	Premium	Premium	See Remarks
2023-04-03	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2022-05-24	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-04-04	Premium	sold	Premium	Premium	Premium	See Remarks
2022-04-04	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2022-03-03	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-02-04	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-02-04	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2021-04-20	Premium	acquired	Premium	Premium	Premium	-
2021-04-20	Premium	acquired	Premium	Premium	Premium	-
2021-03-10	Premium	acquired	Premium	Premium	Premium	See Remarks
2021-03-10	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2021-03-10	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2020-03-10	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2020-03-10	Premium	acquired	Premium	Premium	Premium	See Remarks
2019-12-13	Premium	bought	Premium	Premium	Premium	-
2019-09-23	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2019-09-23	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2019-09-23	Premium	acquired	Premium	Premium	Premium	See Remarks
2019-02-13	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2019-02-12	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer

SYBX - Synlogic Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SYBX